JP2008504277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504277A5 JP2008504277A5 JP2007518296A JP2007518296A JP2008504277A5 JP 2008504277 A5 JP2008504277 A5 JP 2008504277A5 JP 2007518296 A JP2007518296 A JP 2007518296A JP 2007518296 A JP2007518296 A JP 2007518296A JP 2008504277 A5 JP2008504277 A5 JP 2008504277A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- trifluoromethyl
- benzyl
- tetrazol
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 64
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- -1 3,5-bistrifluoromethylbenzyl Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 9
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatoms Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 2
- 206010058108 Dyslipidaemia Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- HLTWGFKVNPAPIK-UHFFFAOYSA-N propan-2-yl 1H-indene-5-carboxylate Chemical compound CC(C)OC(=O)C1=CC=C2CC=CC2=C1 HLTWGFKVNPAPIK-UHFFFAOYSA-N 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- WGJBMEKISIWTOU-ZDGMYTEDSA-N (2S)-3-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-2-methylpropanoic acid Chemical compound C12=CC(C)=C(C(F)(F)F)C=C2N(C[C@H](C)C(O)=O)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGJBMEKISIWTOU-ZDGMYTEDSA-N 0.000 claims 1
- FJPOLBMQNVNQJC-DEOSSOPVSA-N (3-methoxy-2,2-dimethyl-3-oxopropyl) (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC=3CCCC=3C=C21)C(=O)OCC(C)(C)C(=O)OC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FJPOLBMQNVNQJC-DEOSSOPVSA-N 0.000 claims 1
- XPHIEEJLRHUBSX-IBGZPJMESA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,7-dimethyl-N-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XPHIEEJLRHUBSX-IBGZPJMESA-N 0.000 claims 1
- FIMOBMQLBHUGEN-VWLOTQADSA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-N-(2-methyltetrazol-5-yl)-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC3CCCC3)CCC2)=N1 FIMOBMQLBHUGEN-VWLOTQADSA-N 0.000 claims 1
- LUEDXMVWKYTHAI-SANMLTNESA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-N-(2-methyltetrazol-5-yl)-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4CCCC=4C=C3N(CC3CCCC3)CCC2)=N1 LUEDXMVWKYTHAI-SANMLTNESA-N 0.000 claims 1
- XJVKFWFJXZOJRC-FQEVSTJZSA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-7-methyl-N-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XJVKFWFJXZOJRC-FQEVSTJZSA-N 0.000 claims 1
- NNGQXKJWPHTALS-IBGZPJMESA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-N-(2-methyltetrazol-5-yl)-1-(2H-tetrazol-5-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC=1N=NNN=1 NNGQXKJWPHTALS-IBGZPJMESA-N 0.000 claims 1
- PFVYSWIWCUSXDJ-DEOSSOPVSA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-N-(2-methyltetrazol-5-yl)-1-(piperidin-4-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CCNCC1 PFVYSWIWCUSXDJ-DEOSSOPVSA-N 0.000 claims 1
- WJZVHBFKTYFQLJ-DEOSSOPVSA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-N-(2-methyltetrazol-5-yl)-1-(pyridin-4-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=NC=C1 WJZVHBFKTYFQLJ-DEOSSOPVSA-N 0.000 claims 1
- AUZDLAWXAUEWHC-JIDHJSLPSA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-N-(2-methyltetrazol-5-yl)-1-(pyridin-4-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine;hydrochloride Chemical compound Cl.C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=NC=C1 AUZDLAWXAUEWHC-JIDHJSLPSA-N 0.000 claims 1
- CRGOATIHHLWYTC-VWLOTQADSA-N (5S)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-(2-methyltetrazol-5-yl)-1-(pyridin-4-ylmethyl)-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC=3C=CN=CC=3)CCC2)=N1 CRGOATIHHLWYTC-VWLOTQADSA-N 0.000 claims 1
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 1
- BEIJZIGQSAGXEC-NRFANRHFSA-N 2-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]ethanol Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CCO)CCC2)=N1 BEIJZIGQSAGXEC-NRFANRHFSA-N 0.000 claims 1
- SFSZUUNKFVUKGS-FQEVSTJZSA-N 2-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethanol Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCO)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SFSZUUNKFVUKGS-FQEVSTJZSA-N 0.000 claims 1
- NQUZWBZHYJTRFZ-NRFANRHFSA-N 2-[2-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethoxy]acetic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCOCC(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NQUZWBZHYJTRFZ-NRFANRHFSA-N 0.000 claims 1
- DJNZBQFUPNFHIY-IRQSHYTFSA-N 2-[4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]methyl]cyclohexyl]acetic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC3CCC(CC(O)=O)CC3)CCC2)=N1 DJNZBQFUPNFHIY-IRQSHYTFSA-N 0.000 claims 1
- WFDUVYKBQNFEHP-SANMLTNESA-N 2-[4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]phenyl]acetic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(CC(O)=O)C=C1 WFDUVYKBQNFEHP-SANMLTNESA-N 0.000 claims 1
- FKFCLPIIFIDPKI-VWLOTQADSA-N 2-[4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]piperidin-1-yl]acetic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CCN(CC(O)=O)CC1 FKFCLPIIFIDPKI-VWLOTQADSA-N 0.000 claims 1
- WQZRSLLOECZVHP-UHFFFAOYSA-N 2-[4-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexyl]acetic acid Chemical compound C1=2C=C(C(F)(F)F)C(C)=CC=2C(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCCN1CC1CCC(CC(O)=O)CC1 WQZRSLLOECZVHP-UHFFFAOYSA-N 0.000 claims 1
- BRPWZGZBDZUXCA-UHFFFAOYSA-N 2-[4-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(3-methyl-1,2-oxazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexyl]acetic acid Chemical compound O1N=C(C)C=C1N(C1C2=CC(C)=C(C=C2N(CC2CCC(CC(O)=O)CC2)CCC1)C(F)(F)F)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BRPWZGZBDZUXCA-UHFFFAOYSA-N 0.000 claims 1
- IFWLEWADLFGEGJ-VWLOTQADSA-N 2-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(5S)-1-(cyclopentylmethyl)-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-yl]amino]tetrazol-2-yl]ethanol Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(CCO)N=N2)CCN1CC1CCCC1 IFWLEWADLFGEGJ-VWLOTQADSA-N 0.000 claims 1
- MULHIOPENWZDGA-FQEVSTJZSA-N 2-aminoethyl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(C(=O)OCCN)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MULHIOPENWZDGA-FQEVSTJZSA-N 0.000 claims 1
- DQUSXMBTTSCQQO-LFQPHHBNSA-N 2-methylpentan-3-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)C(=O)OC(CC)C(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DQUSXMBTTSCQQO-LFQPHHBNSA-N 0.000 claims 1
- CGMBVYQVWCBALY-QHCPKHFHSA-N 3-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carbonyl]oxy-2,2-dimethylpropanoic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4CCCC=4C=C3N(C(=O)OCC(C)(C)C(O)=O)CCC2)=N1 CGMBVYQVWCBALY-QHCPKHFHSA-N 0.000 claims 1
- GOIUOUZURFSWCG-NRFANRHFSA-N 3-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl]oxy-2,2-dimethylpropanoic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(C(=O)OCC(C)(C)C(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GOIUOUZURFSWCG-NRFANRHFSA-N 0.000 claims 1
- TZVBICPTKXRYME-VWLOTQADSA-N 3-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=CC(C(O)=O)=C1 TZVBICPTKXRYME-VWLOTQADSA-N 0.000 claims 1
- XIXGBCXDMXBYBU-DEOSSOPVSA-N 4-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1C1=CC=C(C(O)=O)C=C1 XIXGBCXDMXBYBU-DEOSSOPVSA-N 0.000 claims 1
- UFXCYRLCVZFMNQ-VWLOTQADSA-N 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(C(O)=O)C=C1 UFXCYRLCVZFMNQ-VWLOTQADSA-N 0.000 claims 1
- BIYYZNPVJCJREK-DEOSSOPVSA-N 5-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]-3,3-dimethylpentanoic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CCC(C)(C)CC(O)=O)CCC2)=N1 BIYYZNPVJCJREK-DEOSSOPVSA-N 0.000 claims 1
- QFNSBPIESHLPIE-VWLOTQADSA-N 5-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxyethyl)tetrazol-5-yl]amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]-3,3-dimethylpentanoic acid Chemical compound N1=NN(CCO)N=C1N([C@H]1CCCN(C2=CC=3COCC=3C=C21)CCC(C)(C)CC(O)=O)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QFNSBPIESHLPIE-VWLOTQADSA-N 0.000 claims 1
- ZDKDDGYIIGDYRT-QHCPKHFHSA-N 5-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]methyl]thiophene-2-carboxylic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC=3SC(=CC=3)C(O)=O)CCC2)=N1 ZDKDDGYIIGDYRT-QHCPKHFHSA-N 0.000 claims 1
- NOFMZHKFQDYPSS-QFIPXVFZSA-N 5-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]thiophene-2-carboxylic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(C(O)=O)S1 NOFMZHKFQDYPSS-QFIPXVFZSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- SKRDXYBATCVEMS-UHFFFAOYSA-N Isopropyl nitrite Chemical compound CC(C)ON=O SKRDXYBATCVEMS-UHFFFAOYSA-N 0.000 claims 1
- LPKMGYHNCFNWCR-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-N-(2-methyltetrazol-5-yl)-2,3,4,5,7,8,9,10-octahydrobenzo[h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2C3=CC=4CCCCC=4C=C3N(CC3CCCC3)CCC2)=N1 LPKMGYHNCFNWCR-UHFFFAOYSA-N 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 230000036823 Plasma Levels Effects 0.000 claims 1
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- XITPLNUGVMFLRK-QHCPKHFHSA-N cyclopentyl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1C(=O)OC1CCCC1 XITPLNUGVMFLRK-QHCPKHFHSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- GBFATWBODAFVEU-FQEVSTJZSA-N ethyl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)C(=O)OCC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GBFATWBODAFVEU-FQEVSTJZSA-N 0.000 claims 1
- GYEKKNSJCCQNQX-MHZLTWQESA-N ethyl 2-[4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]piperidin-1-yl]acetate Chemical compound C1CN(CC(=O)OCC)CCC1CN1C2=CC(C(F)(F)F)=C(C)C=C2[C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC1 GYEKKNSJCCQNQX-MHZLTWQESA-N 0.000 claims 1
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- SZESGYMIZWMYDX-UHFFFAOYSA-N methyl 2-[4-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(3-methyl-1,2-oxazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexyl]acetate Chemical compound C1CC(CC(=O)OC)CCC1CN1C2=CC(C(F)(F)F)=C(C)C=C2C(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C=2ON=C(C)C=2)CCC1 SZESGYMIZWMYDX-UHFFFAOYSA-N 0.000 claims 1
- OOUSUYBNSIFBRY-SANMLTNESA-N methyl 3-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoate Chemical compound COC(=O)C1=CC=CC(CN2C3=CC(=C(C)C=C3[C@@H](N(CC=3C=C(C=C(C=3)C(F)(F)F)C(F)(F)F)C3=NN(C)N=N3)CCC2)C(F)(F)F)=C1 OOUSUYBNSIFBRY-SANMLTNESA-N 0.000 claims 1
- CNCAXBRVYBNCPG-SANMLTNESA-N methyl 4-[[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C2=CC(C(F)(F)F)=C(C)C=C2[C@@H](N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCC1 CNCAXBRVYBNCPG-SANMLTNESA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- DSQNFULSOJERBB-QHCPKHFHSA-N oxan-4-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1C(=O)OC1CCOCC1 DSQNFULSOJERBB-QHCPKHFHSA-N 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
- XNVIGELDDWQMPP-QHCPKHFHSA-N pentan-3-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)C(=O)OC(CC)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XNVIGELDDWQMPP-QHCPKHFHSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- DVPOEQYHIZNFLH-HSZRJFAPSA-N propan-2-yl (5R)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@@H]1CCCN(C2=CC=3CCCC=3C=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DVPOEQYHIZNFLH-HSZRJFAPSA-N 0.000 claims 1
- DAFQXBZNJZQTKI-QFIPXVFZSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC=3COCC=3C=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DAFQXBZNJZQTKI-QFIPXVFZSA-N 0.000 claims 1
- DVPOEQYHIZNFLH-QHCPKHFHSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC=3CCCC=3C=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DVPOEQYHIZNFLH-QHCPKHFHSA-N 0.000 claims 1
- XXBYALLEYGCVLW-DEOSSOPVSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-3,4,5,8,9,10-hexahydro-2H-cyclopenta[i][1]benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=C3CCCC3=C(C)C=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XXBYALLEYGCVLW-DEOSSOPVSA-N 0.000 claims 1
- NJOMLQFRPPNZOD-NRFANRHFSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NJOMLQFRPPNZOD-NRFANRHFSA-N 0.000 claims 1
- JGYFOQYFSSXJHV-QFIPXVFZSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-8,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=C(C)C(C)=CC=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JGYFOQYFSSXJHV-QFIPXVFZSA-N 0.000 claims 1
- VRJSPBBAONBYEC-VWLOTQADSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxyethyl)tetrazol-5-yl]amino]-7-methyl-3,4,5,8,9,10-hexahydro-2H-cyclopenta[i][1]benzazepine-1-carboxylate Chemical compound N1=NN(CCO)N=C1N([C@H]1CCCN(C2=C3CCCC3=C(C)C=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 VRJSPBBAONBYEC-VWLOTQADSA-N 0.000 claims 1
- NQJUOWYPUVKYTM-QHCPKHFHSA-N propan-2-yl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxyethyl)tetrazol-5-yl]amino]-8,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(CCO)N=C1N([C@H]1CCCN(C2=C(C)C(C)=CC=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NQJUOWYPUVKYTM-QHCPKHFHSA-N 0.000 claims 1
- PAAMHDIEMJHSPM-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,8,9,10-octahydrobenzo[h][1]benzazepine-1-carboxylate Chemical compound C12=CC=3CCCCC=3C=C2N(C(=O)OC(C)C)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 PAAMHDIEMJHSPM-UHFFFAOYSA-N 0.000 claims 1
- DVPOEQYHIZNFLH-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carboxylate Chemical compound C12=CC=3CCCC=3C=C2N(C(=O)OC(C)C)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DVPOEQYHIZNFLH-UHFFFAOYSA-N 0.000 claims 1
- UWWFUIBLXISBCB-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UWWFUIBLXISBCB-UHFFFAOYSA-N 0.000 claims 1
- XSRGXANGXYYSLC-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2H-tetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carboxylate Chemical compound C12=CC=3CCCC=3C=C2N(C(=O)OC(C)C)CCCC1N(C1=NNN=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XSRGXANGXYYSLC-UHFFFAOYSA-N 0.000 claims 1
- OHBFCIQJIARLEG-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2H-tetrazol-5-yl)amino]-3,4,5,8,9,10-hexahydro-2H-cyclopenta[i][1]benzazepine-1-carboxylate Chemical compound C12=CC=C3CCCC3=C2N(C(=O)OC(C)C)CCCC1N(C1=NNN=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OHBFCIQJIARLEG-UHFFFAOYSA-N 0.000 claims 1
- RXZOHYMVEIIJBK-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2H-tetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC(C)=C(C(F)(F)F)C=C2N(C(=O)OC(C)C)CCCC1N(C=1NN=NN=1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RXZOHYMVEIIJBK-UHFFFAOYSA-N 0.000 claims 1
- OKOIBAJDFPVHSX-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2H-tetrazol-5-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C=1NN=NN=1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OKOIBAJDFPVHSX-UHFFFAOYSA-N 0.000 claims 1
- JNYUKXLOCJSLJF-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-methyl-1H-pyrazol-3-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C1=NNC(C)=C1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JNYUKXLOCJSLJF-UHFFFAOYSA-N 0.000 claims 1
- WQJOJBGYFCMEHK-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-methyl-2H-1,2-oxazol-5-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C1(C)C=CNO1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WQJOJBGYFCMEHK-UHFFFAOYSA-N 0.000 claims 1
- GTMFLRLAOYVQAO-QFIPXVFZSA-N tert-butyl (5S)-5-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(CCN)N=C1N([C@@H]1C=2C=C(C(=CC=2N(C(=O)OC(C)(C)C)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 GTMFLRLAOYVQAO-QFIPXVFZSA-N 0.000 claims 1
- UIADFZNXRVKQNY-QHCPKHFHSA-N tert-butyl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2H-cyclopenta[h][1]benzazepine-1-carboxylate Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4CCCC=4C=C3N(C(=O)OC(C)(C)C)CCC2)=N1 UIADFZNXRVKQNY-QHCPKHFHSA-N 0.000 claims 1
- OHFQGIGQVDLYLJ-NRFANRHFSA-N tert-butyl (5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(C(=O)OC(C)(C)C)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OHFQGIGQVDLYLJ-NRFANRHFSA-N 0.000 claims 1
- JUKWZDOXLZRSRS-UHFFFAOYSA-N tert-butyl 1H-indene-5-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC=C2CC=CC2=C1 JUKWZDOXLZRSRS-UHFFFAOYSA-N 0.000 claims 1
- RSWQLSGHWCNKOC-DEOSSOPVSA-N tert-butyl N-[2-[(5S)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-ethyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethyl]carbamate Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCNC(=O)OC(C)(C)C)CCC1)C(F)(F)F)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RSWQLSGHWCNKOC-DEOSSOPVSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (16)
(式中、
nは、0、1、2、又は3であり、
mは、0、1、2、又は3であり、
pは、1または2であり、
qは、0、1、2、3又は4であり、
Yは、結合、C=O又はS(O)tであり、ここで、tは、0、1又は2であり、
R1は、ヒドロキシ、C1−C6アルキル、アリール、C2−C6アルケニル、C1−C6ハロアルキル、C1−C6アルキルヘテロシクリル、C3−C8シクロアルキル、C1−C6アルキルシクロアルキル、C1−C6アルキルアリール、ヘテロシクリル、C1−C6ヒドロキシアルキル、C1−C6アルコキシ、−Oアリール、−OC2−C6アルケニル、−OC1−C6ハロアルキル、−OC1−C6アルキルヘテロシクリル、−OC3−C8シクロアルキル、−OC1−C6アルキルシクロアルキル、−NR7R8及び−OC1−C6アルキルアリール、−O−ヘテロシクリル、−OC1−C6アルキルヘテロシクリル、C1−C6アルキル−O−C(O)NR7R8、C1−C6アルキル−NR7C(O)NR7R8、及びC0−C6アルキルCOOR11からなる群より選ばれ、但し、YがS(O)tである場合R1がヒドロキシではなく、シクロアルキル、アリール、及び複素環基の各々が、オキソ、ヒドロキシ、ハロゲン、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6アルコキシ、C1−C6ハロアルキル、C1−C6ヒドロキシアルキル、CONR11R12、NR11SO2R12、NR11COR12、C0−C3アルキルNR11R12、C1−C3アルキルCOR11、C0−C6アルキルCOOR11、シアノ、C1−C6アルキルシクロアルキル、フェニル、−OC1−C6アルキルシクロアルキル、−OC1−C6アルキルアリール、−OC1−C6アルキルヘテロシクリル、及びC1−C6アルキルアリールから独立して選択される1〜3個の基で任意に置換され、
R2の各々は、炭素原子にのみ結合し、水素、ヒドロキシ、ハロゲン、オキソ、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6アルコキシ、C1−C6ハロアルキル、CONR11R12、−NR11SO2R12、−NR11COR12、C0−C6アルキルNR11R12、C0−C6アルキルCOR11、C0−C6アルキルCOOR11、シアノ、ニトロ、C0−C6アルキルシクロアルキル、フェニル、C0−C6アルキルアリール、ヘテロシクリル、C3−C8シクロアルキル、及びC1−C6ハロアルキルからなる群からそれぞれ独立して選択される基であり、但し、独立して選ばれる2つのR2基は、任意にジェム二置換されており、
R3a及びR3bは、水素、ハロゲン、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6アルコキシ、及びC1−C6ハロアルキルからなる群から独立して選択され、
R4は、式−NR4aR4bによって表される基であり、
R4aは、オキソ、ヒドロキシル、ハロゲン、−NR11R12、C1−C6アルキル、C2−C6アルケニル、C0−C6アルキルCN、C1−C6アルコキシ、C1−C6ヒドロキシアルキル、C1−C6ハロアルキル、−OC(O)NR11R12、C1−C6アルキルNR11R12からなる群より独立して選択される1〜3個の基によって各複素環基が任意に置換されるヘテロシクリル、C1−C6アルキルヘテロシクリル、又はC2−C6アルケニル複素環基であり、C1−C6アルキル基が、−OR10又はC(O)OR10、C0−C6アルキルNO2、C0−C6アルキルNR11SO2R12、C0−C6アルキルC(O)NR11R12、C0−C6アルキルNR11C(O)R12、C0−C6アルキルNR11C(O)OR12、C0−C6アルキルNR11C(O)NR10R12、C0−C6アルキルNR11CHR10CO2R12、C0−C6アルキルC(O)OR11、C0−C6アルキルSO2NR11R12、C0−C6アルキルS(O)tR11、C3−C8シクロアルキル、C1−C6アルキルシクロアルキル、及びC0−C6アルキルヘテロシクリルによって任意に置換され、C0−C6アルキル複素環基の複素環が、ハロ、C1−C6アルキル、オキソ、−CO2R11、及び−NR11R12によって任意に置換され、
R4bは、C1−C6アルキルアリール、C2−C6アルケニルアリール、C2−C6アルキニルアリール、C1−C6アルキルヘテロシクリル、C2−C6アルケニルヘテロシクリル、C1−C6アルキルシクロアルキル、及びC1−C6アルキル−O−C1−C6アルキルアリールからなる群より選択され、ここで、シクロアルキル、アリール、又は複素環基の各々が、ヒドロキシ、オキソ、−SC1−C6アルキル、C1−C6アルキル、C1−C6アルケニル、C1−C6アルキニル、C1−C6ハロアルキル、ハロゲン、C1−C6アルコキシ、アリールオキシ、C1−C6アルケニルオキシ、C1−C6ハロアルコキシアルキル、C0−C6アルキルNR11R12、−OC1−C6アルキルアリール、ニトロ、シアノ、C1−C6ハロアルキルアルコール、及びC1−C6ヒドロキシアルキルからなる群より独立して選択される1〜3個の基で任意に置換され、
R5は、水素、ヒドロキシ、ハロゲン、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、C1−C6アルコキシ、アリールオキシ、−OC2−C6アルケニル、−OC1−C6ハロアルキル、C1−C6ハロアルキル、C3−C8シクロアルキル、C1−C6アルキルアリール、C1−C6アルキルヘテロシクリル、C2−C6アルケニルアリール、C2−C6アルケニルヘテロシクリル、アリール、ヘテロシクリル、シアノ、ニトロ、C0−C6アルキルNR7R8、C0−C6アルキルCOR7、C0−C6アルキルCO2R7、C0−C6アルキルCONR7R8、CONR7SO2R8、−NR7SO2R8、−NR7COR8、−N=CR7R8、−OCONR7R8、−S(O)tR7、−SO2NR7R8、C0−C5CH2OH、−OC1−C6アルキルヘテロシクリル、及び−OC1−C6アルキルアリールからなる群より選ばれ、ここで、アルキル、アルケニル、アルキニル、シクロアルキル、アリール、および複素環基またはサブグループの各々が、オキソ、アルキルオキシ、アリールオキシによって任意に置換され、
かつ、2個のR5基が結合して、これらの基が結合するフェニル環(A環)とともに、置換されていてもよい5、6、又は7員の縮合環を形成し、該5、6、又は7員縮合環は、飽和、部分的に不飽和、又は完全に不飽和であり、O、N、及びSから独立して選択される1、2、又は3個のヘテロ原子を含んでいてもよく、
R6は、水素、C1−C6アルキル、C2−C6アルケニル、ヒドロキシ、COR7、C1−C6アルコキシ、アリールオキシ、−OC2−C6アルケニル、−OC1−C6ハロアルキル、C1−C6アルキルNR7R8、C3−C8シクロアルキル、ヘテロシクリル、アリール、C1−C6アルキル−O−C(O)NR7R8、C1−C6アルキル−NR7C(O)NR7R8、及びC1−C6アルキルシクロアルキルからなる群から独立して選択され、
R7及びR8は、水素、C1−C6アルキル、C2−C6アルケニル、C2−C6アルキニル、−OC1−C6アルキル、C1−C6ハロアルキル、−O−アリール、−OC3−C8シクロアルキル、−O−ヘテロシクリル、−NR7R8、−C1−C6アルキルシクロアルキル、−OC1−C6アルキルシクロアルキル、−OC1−C6アルキルヘテロシクリル、C1−C6アルキルヘテロシクリル、−OC1−C6アルキルアリール、C3−C8シクロアルキル、ヘテロシクリル、アリール、及びC1−C6アルキルアリールからなる群からそれぞれ独立して選択され、ここで、アルキル、シクロアルキル、ヘテロシクリル、又はアリール基の各々が、ヒドロキシ、CN、ハロゲン、C1−C6アルキル、C1−C6アルコキシ、C1−C6ハロアルキル、及び−NR11R12から独立して選択される1〜3個の基によって任意に置換され、或いは、R7及びR8は結合して酸素、窒素、及び硫黄から選択される0、1、又は2個のさらなるヘテロ原子を有する窒素含有複素環を形成し、ここで、窒素含有複素環が、オキソ又はC1−C6アルキルによって任意に置換され、
R10、R11、及びR12は、水素、C1−C6アルキル、C1−C6アルケニル、C3−C8シクロアルキル、ヘテロシクリル、アリール、C1−C6アルキルアリールからなる群から独立して選択され、ここで、アルキル、アリール、シクロアルキル、及び複素環基の各々が、ハロゲン、C1−C6アルキルヘテロシクリル、及びC1−C6ハロアルキルから独立して選択される1〜3個の基によって任意に置換されるか、またはR11及びR12が結合して酸素、窒素又は硫黄から選択される0、1、又は2個のさらなるヘテロ原子を有し、オキソ、C1−C6アルキル、COR7、及び−SO2R7によって任意に置換される窒素含有複素環を形成する。) A compound of formula I, or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.
(Where
n is 0, 1, 2, or 3;
m is 0, 1, 2, or 3;
p is 1 or 2,
q is 0, 1, 2, 3 or 4;
Y is a bond, C═O or S (O) t , where t is 0, 1 or 2;
R 1 is hydroxy, C 1 -C 6 alkyl, aryl, C 2 -C 6 alkenyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl heterocyclyl, C 3 -C 8 cycloalkyl, C 1 -C 6. Alkylcycloalkyl, C 1 -C 6 alkylaryl, heterocyclyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxy, -O aryl, -OC 2 -C 6 alkenyl, -OC 1 -C 6 haloalkyl,- OC 1 -C 6 alkylheterocyclyl, -OC 3 -C 8 cycloalkyl, -OC 1 -C 6 alkylcycloalkyl, -NR 7 R 8 and -OC 1 -C 6 alkylaryl, -O- heterocyclyl, -OC 1 -C 6 alkylheterocyclyl, C 1 -C 6 alkyl -O-C (O) NR 7 R 8, C 1 -C 6 A Kill -NR 7 C (O) NR 7 R 8, and selected from the group consisting of C 0 -C 6 alkyl COOR 11, however, Y is not a S (O) if a t R 1 is hydroxy, cycloalkyl , aryl, and each of the heterocyclic groups, oxo, hydroxy, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 6 Haloalkyl, C 1 -C 6 hydroxyalkyl, CONR 11 R 12 , NR 11 SO 2 R 12 , NR 11 COR 12 , C 0 -C 3 alkyl NR 11 R 12 , C 1 -C 3 alkyl COR 11 , C 0- C 6 alkyl COOR 11 , cyano, C 1 -C 6 alkyl cycloalkyl, phenyl, —OC 1 -C 6 alkyl cycloalkyl, —OC 1 — C 6 alkylaryl, optionally substituted with one to three groups independently selected -OC 1 -C 6 alkylheterocyclyl, and C 1 -C 6 alkylaryl,
Each of R 2 is bonded only to a carbon atom and is hydrogen, hydroxy, halogen, oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1- C 6 haloalkyl, CONR 11 R 12 , —NR 11 SO 2 R 12 , —NR 11 COR 12 , C 0 -C 6 alkyl NR 11 R 12 , C 0 -C 6 alkyl COR 11 , C 0 -C 6 alkyl COOR 11, cyano, nitro, C 0 -C 6 alkylcycloalkyl, phenyl, C 0 -C 6 alkylaryl, heterocyclyl, each independently C 3 -C 8 cycloalkyl, and a C 1 -C 6 group consisting of haloalkyl Wherein two independently selected R 2 groups are optionally gem-disubstituted,
R 3a and R 3b are selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, and C 1 -C 6 haloalkyl. Independently selected,
R 4 is a group represented by the formula —NR 4a R 4b ,
R 4a is oxo, hydroxyl, halogen, —NR 11 R 12 , C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 0 -C 6 alkyl CN, C 1 -C 6 alkoxy, C 1 -C 6. hydroxy alkyl, C 1 -C 6 haloalkyl, -OC (O) NR 11 R 12, C 1 -C 6 alkyl NR 11 each heterocycle by one to three groups independently selected from the group consisting of R 12 heterocyclyl group is optionally substituted, C 1 -C 6 alkylheterocyclyl, or a C 2 -C 6 alkenyl heterocyclic group, C 1 -C 6 alkyl is, -OR 10 or C (O) oR 10, C 0 -C 6 alkyl NO 2 , C 0 -C 6 alkyl NR 11 SO 2 R 12 , C 0 -C 6 alkyl C (O) NR 11 R 12 , C 0 -C 6 alkyl NR 1 1 C (O) R 12 , C 0 -C 6 alkyl NR 11 C (O) OR 12 , C 0 -C 6 alkyl NR 11 C (O) NR 10 R 12 , C 0 -C 6 alkyl NR 11 CHR 10 CO 2 R 12 , C 0 -C 6 alkyl C (O) OR 11 , C 0 -C 6 alkyl SO 2 NR 11 R 12 , C 0 -C 6 alkyl S (O) t R 11 , C 3 -C 8 Optionally substituted by cycloalkyl, C 1 -C 6 alkyl cycloalkyl, and C 0 -C 6 alkyl heterocyclyl, the heterocycle of the C 0 -C 6 alkyl heterocycle group is halo, C 1 -C 6 alkyl, oxo , —CO 2 R 11 , and —NR 11 R 12 ,
R 4b is C 1 -C 6 alkylaryl, C 2 -C 6 alkenyl aryl, C 2 -C 6 alkynyl aryl, C 1 -C 6 alkyl heterocyclyl, C 2 -C 6 alkenyl heterocyclyl, C 1 -C 6 alkyl. Selected from the group consisting of cycloalkyl, and C 1 -C 6 alkyl-O—C 1 -C 6 alkylaryl, wherein each cycloalkyl, aryl, or heterocyclic group is hydroxy, oxo, —SC 1 -C 6 alkyl, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, C 1 -C 6 haloalkyl, halogen, C 1 -C 6 alkoxy, aryloxy, C 1 -C 6 alkenyloxy, C 1 -C 6 haloalkoxyalkyl, C 0 -C 6 alkyl NR 11 R 12, -OC 1 -C 6 Rukiruariru, substituted nitro, cyano, optionally with C 1 -C 6 halo alkyl alcohol, and C 1 -C 6 1 to 3 groups selected independently from the group consisting of hydroxyalkyl,
R 5 is hydrogen, hydroxy, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, aryloxy, -OC 2 -C 6 alkenyl,- OC 1 -C 6 haloalkyl, C 1 -C 6 haloalkyl, C 3 -C 8 cycloalkyl, C 1 -C 6 alkylaryl, C 1 -C 6 alkylheterocyclyl, C 2 -C 6 alkenylaryl, C 2 -C 6 alkenyl heterocyclyl, aryl, heterocyclyl, cyano, nitro, C 0 -C 6 alkyl NR 7 R 8 , C 0 -C 6 alkyl COR 7 , C 0 -C 6 alkyl CO 2 R 7 , C 0 -C 6 alkyl CONR 7 R 8, CONR 7 SO 2 R 8, -NR 7 SO 2 R 8, -NR 7 COR 8, -N = CR 7 R 8 -OCONR 7 R 8, -S (O ) t R 7, -SO 2 NR 7 R 8, C 0 -C 5 CH 2 OH, -OC 1 -C 6 alkylheterocyclyl, and -OC 1 -C 6 alkylaryl Wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclic groups or subgroups are optionally substituted by oxo, alkyloxy, aryloxy,
And two R 5 groups are bonded to form a 5-, 6- or 7-membered condensed ring optionally substituted with the phenyl ring to which these groups are bonded (A ring), 6- or 7-membered fused rings are saturated, partially unsaturated, or fully unsaturated and contain 1, 2, or 3 heteroatoms independently selected from O, N, and S You can leave
R 6 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, hydroxy, COR 7 , C 1 -C 6 alkoxy, aryloxy, -OC 2 -C 6 alkenyl, -OC 1 -C 6 haloalkyl , C 1 -C 6 alkyl NR 7 R 8, C 3 -C 8 cycloalkyl, heterocyclyl, aryl, C 1 -C 6 alkyl -O-C (O) NR 7 R 8, C 1 -C 6 alkyl -NR Independently selected from the group consisting of 7 C (O) NR 7 R 8 , and C 1 -C 6 alkylcycloalkyl;
R 7 and R 8 are hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -OC 1 -C 6 alkyl, C 1 -C 6 haloalkyl, -O-aryl, -OC 3 -C 8 cycloalkyl, -O- heterocyclyl, -NR 7 R 8, -C 1 -C 6 alkylcycloalkyl, -OC 1 -C 6 alkylcycloalkyl, -OC 1 -C 6 alkylheterocyclyl, C 1 -C 6 alkylheterocyclyl, -OC 1 -C 6 alkylaryl, C 3 -C 8 cycloalkyl, heterocyclyl, aryl, and are each independently selected from C 1 -C consisting of 6 alkylaryl group, wherein alkyl, cycloalkyl, heterocyclyl, or each aryl group, hydroxy, CN, halogen, C 1 -C 6 alkyl , C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, and -NR 11 are optionally substituted by one to three groups independently selected from R 12, or, R 7 and R 8 are bonded Forming a nitrogen-containing heterocycle having 0, 1, or 2 additional heteroatoms selected from oxygen, nitrogen, and sulfur, wherein the nitrogen-containing heterocycle is oxo or C 1 -C 6 alkyl Optionally substituted,
R 10 , R 11 , and R 12 are selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 3 -C 8 cycloalkyl, heterocyclyl, aryl, C 1 -C 6 alkylaryl. Independently selected, wherein each of the alkyl, aryl, cycloalkyl, and heterocyclic groups is independently selected from halogen, C 1 -C 6 alkyl heterocyclyl, and C 1 -C 6 haloalkyl Optionally substituted by 3 groups, or R 11 and R 12 are combined and have 0, 1, or 2 additional heteroatoms selected from oxygen, nitrogen or sulfur, oxo, C 1 -C 6 alkyl, COR 7, and to form a nitrogen-containing heterocyclic ring optionally substituted by -SO 2 R 7. )
R4aは、
R 4a is
5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(1H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸イソプロピルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸エチルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸イソプロピルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸tert−ブチルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸1−エチル−プロピルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸シクロペンチルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸1−エチル−2−メチル−プロピルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸テトラヒドロ−ピラン−4−イルエステル、
(S)−2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(1−シクロペンチルメチル−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−アミノ]−テトラゾール−2−イル}−エタノール、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(1−エチル−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−シクロヘキシル)−酢酸、
(S)−5−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−3,3−ジメチル−ペンタン酸、
(S)−2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−エタノール、
(+/−)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2H−テトラゾール−5−イル)−アミノ]−2,2−ジフルオロ−6,7,8,9−テトラヒドロ−1,3−ジオキサ−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(+/−)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,2−ジフルオロ−6,7,8,9−テトラヒドロ−1,3−ジオキサ−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(+/−)−イソプロピル5−[(3,5−ビストリフルオロメチル−ベンジル)−(1H−テトラゾール−5−イル)−アミノ]−8−クロロ−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(+/−)−イソプロピル5−[(3,5−ビストリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−8−クロロ−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(+/−)イソプロピル−6−[(3,5−ビストリフルオロメチル−ベンジル)−(1H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−10−アザ−シクロヘプタ[e]インデン−10−カルボン酸塩、
(+/−)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(+/−)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(+/−)−イソプロピル5−[(3,5−ビストリフルオロメチル−ベンジル)−(5−メチル−1H−ピラゾール−3−イル)−アミノ]−8−クロロ−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(+/−)−イソプロピル5−[(3,5−ビストリフルオロメチル−ベンジル)−(5−メチル−イソオキサゾール−5−イル)−アミノ]−8−クロロ−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(+/−)−イソプロピル5−[(3,5−ビストリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−9−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(S)−6−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−4−メチル−2,3,6,7,8,9−ヘキサヒドロ−1H−10−アザ−シクロヘプタ[e]インデン−10−カルボン酸イソプロピルエステル、
(S)−イソプロピル5−[(3,5−ビストリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−8,9−ジメチル−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(S)−イソプロピル5−{(3,5−ビス−トリフルオロメチル−ベンジル)−[2−(2−ヒドロキシ−エチル)−2H−テトラゾール−5−イル]−アミノ}−8,9−ジメチル−2,3,4,5−テトラヒドロベンゾ[b]アゼピン−1−カルボン酸塩、
(S)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸tert−ブチルエステル、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(5−シクロペンチルメチル−1,2,3,5,6,7,8,9−オクタヒドロ−5−アザ−シクロヘプタ[f]インデン−9−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(5−シクロペンチルメチル−3,5,6,7,8,9−ヘキサヒドロ−1H−2−オキサ−5−アザ−シクロヘプタ[f]インデン−9−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−5−{9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−イル}−3,3−ジメチル−ペンタン酸、
(S)−5−(9−{(3,5−ビス−トリフルオロメチル−ベンジル)−[2−(2−ヒドロキシ−エチル)−2H−テトラゾール−5−イル]−アミノ}−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−イル)−3,3−ジメチル−ペンタン酸、
(S)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(3,5−ビス−トリフルオロメチル−ベンジル)−(1−シクロペンチルメチル−2,3,4,5,7,8,9,10−オクタヒドロ−1H−ナフト[2,3−b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,4,5,7,8,9,10−オクタヒドロ−ナフト[2,3−b]アゼピン−1−カルボン酸イソプロピルエステル、
(S)−9−{(3,5−ビス−トリフルオロメチル−ベンジル)−[2−(2−ヒドロキシ−エチル)−2H−テトラゾール−5−イル]−アミノ}−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(R)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(S)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸イソプロピルエステル、
(S)−6−{(3,5−ビス−トリフルオロメチル−ベンジル)−[2−(2−ヒドロキシ−エチル)−2H−テトラゾール−5−イル]−アミノ}−2,3,6,7,8,9−ヘキサヒドロ−1H−10−アザ−シクロヘプタ[e]インデン−10−カルボン酸イソプロピルエステル、
(S)−6−{(3,5−ビス−トリフルオロメチル−ベンジル)−[2−(2−ヒドロキシ−エチル)−2H−テトラゾール−5−イル]−アミノ}−4−メチル−2,3,6,7,8,9−ヘキサヒドロ−1H−10−アザ−シクロヘプタ[e]インデン−10−カルボン酸イソプロピルエステル、
(S)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸2−メトキシカルボニル−2−メチル−プロピルエステル、
(S)−9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,6,7,8,9−ヘキサヒドロ−1H−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸2−カルボキシ−2−メチル−プロピルエステル、
(S)−1−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−3−フラン−2−イルメトキシ)−プロパン−2−オン、
2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−1−フェニル−エタノール、
2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−2−フェニル−エタノール、
(S)−4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−安息香酸メチルエステル、
(S)−4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−安息香酸、
(S)−3−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−安息香酸メチルエステル、
(S)−3−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−安息香酸、
(S)−4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−安息香酸、
(4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(3−メチル−イソオキサゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−シクロヘキシル)−酢酸メチルエステル、
(4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(3−メチル−イソオキサゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−シクロヘキシル)−酢酸、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(7−メチル−1−ピリジン−4−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(7−メチル−1−ピリジン−4−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン塩酸塩、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(7−メチル−1−ピリジン−3−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(1−シクロプロピルメチル−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−エチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−エタノール、
(S)−(2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−エチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−エチル)−カルバミン酸tert−ブチルエステル、
(S)−4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−エチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−安息香酸、
(S)5−{9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−イルメチル}−チオフェン−2−カルボン酸、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−(5−ピリジン−4−イルメチル−3,5,6,7,8,9−ヘキサヒドロ−1H−2−オキサ−5−アザ−シクロヘプタ[f]インデン−9−イル)−アミン、
(S)−(4−{9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−イルメチル}−シクロヘキシル)−酢酸、
(S)−2−{9−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−イル}−エタノール、
(S)−9−[[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−アミノ]−1,3,6,7,8,9−ヘキサヒドロ−2−オキサ−5−アザ−シクロヘプタ[f]インデン−5−カルボン酸tert−ブチルエステル、
(S)−[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(5−ベンジル−3,5,6,7,8,9−ヘキサヒドロ−1H−2−オキサ−5−アザ−シクロヘプタ[f]インデン−9−イル)−(3,5−ビス−トリフルオロメチル−ベンジル)−アミン、
(S)−[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−[5−(3,3,3−トリフルオロ−プロピル)−3,5,6,7,8,9−ヘキサヒドロ−1H−2−オキサ−5−アザ−シクロヘプタ[f]インデン−9−イル]−アミン、
(S)−5−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−2,3,4,5,7,8,9,10−オクタヒドロ−ナフト[2,3−b]アゼピン−1−イル}−3,3−ジメチル−ペンタン酸、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(1−シクロペンチルメチル−11−メチル−2,3,4,5,7,8,9,10−オクタヒドロ−1H−ナフト[2,3−b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−5−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−チオフェン−2−カルボン酸、
(S)−5−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−2−メチル−プロピオン酸エチルエステル、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(1,7−ジメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−(7−メチル−1−チアゾール−2−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−アミン、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−[7−メチル−1−(1−メチル−1H−イミダゾール−2−イルメチル)−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル]−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−(1−ベンジル−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−5−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}、
(S)−(4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−フェニル)−酢酸、
(S)−4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−酪酸、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(7−メチル−1−ピペリジン−4−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−(4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−ピペリジン−1−イル)−酢酸エチルエステル、
(S)−(4−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イルメチル}−ピペリジン−1−イル)−酢酸、
(S)−3−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−2−メチル−プロピオン酸、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(7−メチル−1−ピロリジン−2−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−(2−メチル−2H−テトラゾール−5−イル)−アミン、
(S)−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−酢酸、
(S)−[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−[1−(2−ベンジルオキシ−エチル)−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−アミン、
(S)−2−{5−[[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−エタノール、
(S)−5−[[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸tert−ブチルエステル、
(S)−[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−(7−メチル−1−チアゾール−2−イルメチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−アミン、
(S)−(2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−エトキシ)−酢酸、
(S)−酢酸2−{5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−イル}−エチルエステル、
(S)−(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−[7−メチル−1−(2H−テトラゾール−5−イルメチル)−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル]−アミン、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸2−アミノ−エチルエステル、
(S)−5−[(3,5−ビス−トリフルオロメチル−ベンジル)−(2−メチル−2H−テトラゾール−5−イル)−アミノ]−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−ベンゾ[b]アゼピン−1−カルボン酸2−カルボキシ−2−メチル−プロピルエステル、
(S)−[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−(1−シクロプロピルメチル−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−アミン、
(S)−[2−(2−アミノ−エチル)−2H−テトラゾール−5−イル]−(3,5−ビス−トリフルオロメチル−ベンジル)−(1−シクロプロピルメチル−7−メチル−8−トリフルオロメチル−2,3,4,5−テトラヒドロ−1H−ベンゾ[b]アゼピン−5−イル)−アミン塩酸塩
からなる群より選ばれる化合物、又はその薬理学的に許容できる塩、鏡像異性体、ラセミ化合物、ジアステレオマー、もしくはジアステレオマーの混合物。 (S)-(3,5-bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepine-5 -Yl)-(2-methyl-2H-tetrazol-5-yl) amine,
5-[(3,5-bis-trifluoromethyl-benzyl)-(1H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro- Benzo [b] azepine-1-carboxylic acid isopropyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid ethyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid isopropyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid tert-butyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid 1-ethyl-propyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid cyclopentyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid 1-ethyl-2-methyl-propyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid tetrahydro-pyran-4-yl ester,
(S) -2- {5-[(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro- 1H-benzo [b] azepin-5-yl) -amino] -tetrazol-2-yl} -ethanol,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(1-ethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepine -5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -cyclohexyl) -acetic acid,
(S) -5- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -3,3-dimethyl-pentanoic acid,
(S) -2- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -ethanol,
(+/-)-9-[(3,5-bis-trifluoromethyl-benzyl)-(2H-tetrazol-5-yl) -amino] -2,2-difluoro-6,7,8,9- Tetrahydro-1,3-dioxa-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(+/-)-9-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,2-difluoro-6,7, 8,9-tetrahydro-1,3-dioxa-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(+/-)-Isopropyl 5-[(3,5-bistrifluoromethyl-benzyl)-(1H-tetrazol-5-yl) -amino] -8-chloro-2,3,4,5-tetrahydrobenzo [ b] Azepine-1-carboxylate,
(+/-)-Isopropyl 5-[(3,5-bistrifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -8-chloro-2,3,4,5 -Tetrahydrobenzo [b] azepine-1-carboxylate,
(+/-) isopropyl-6-[(3,5-bistrifluoromethyl-benzyl)-(1H-tetrazol-5-yl) -amino] -2,3,6,7,8,9-hexahydro-1H -10-aza-cyclohepta [e] indene-10-carboxylate,
(+/-)-9-[(3,5-bis-trifluoromethyl-benzyl)-(2H-tetrazol-5-yl) -amino] -2,3,6,7,8,9-hexahydro- 1H-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(+/-)-9-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,6,7,8, 9-hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(+/-)-Isopropyl 5-[(3,5-bistrifluoromethyl-benzyl)-(5-methyl-1H-pyrazol-3-yl) -amino] -8-chloro-2,3,4,5 -Tetrahydrobenzo [b] azepine-1-carboxylate,
(+/-)-Isopropyl 5-[(3,5-bistrifluoromethyl-benzyl)-(5-methyl-isoxazol-5-yl) -amino] -8-chloro-2,3,4,5- Tetrahydrobenzo [b] azepine-1-carboxylate,
(+/-)-Isopropyl 5-[(3,5-bistrifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -9-methyl-8-trifluoromethyl-2 , 3,4,5-tetrahydrobenzo [b] azepine-1-carboxylate,
(S) -6-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -4-methyl-2,3,6,7, 8,9-hexahydro-1H-10-aza-cyclohepta [e] indene-10-carboxylic acid isopropyl ester,
(S) -Isopropyl 5-[(3,5-bistrifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -8,9-dimethyl-2,3,4,5 -Tetrahydrobenzo [b] azepine-1-carboxylate,
(S) -Isopropyl 5-{(3,5-bis-trifluoromethyl-benzyl)-[2- (2-hydroxy-ethyl) -2H-tetrazol-5-yl] -amino} -8,9-dimethyl -2,3,4,5-tetrahydrobenzo [b] azepine-1-carboxylate,
(S) -9-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,6,7,8,9- Hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid tert-butyl ester,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(5-cyclopentylmethyl-1,2,3,5,6,7,8,9-octahydro-5-aza-cyclohepta [f] Inden-9-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(5-cyclopentylmethyl-3,5,6,7,8,9-hexahydro-1H-2-oxa-5-aza-cyclohepta [ f] Inden-9-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S) -5- {9-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -1,3,6,7,8 , 9-hexahydro-2-oxa-5-aza-cyclohepta [f] inden-5-yl} -3,3-dimethyl-pentanoic acid,
(S) -5- (9-{(3,5-bis-trifluoromethyl-benzyl)-[2- (2-hydroxy-ethyl) -2H-tetrazol-5-yl] -amino} -1,3 , 6,7,8,9-hexahydro-2-oxa-5-aza-cyclohepta [f] inden-5-yl) -3,3-dimethyl-pentanoic acid,
(S) -9-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -1,3,6,7,8,9- Hexahydro-2-oxa-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopentylmethyl-2,3,4,5,7,8,9,10-octahydro-1H-naphtho [2,3-b] azepine- 5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,4,5,7,8,9,10- Octahydro-naphtho [2,3-b] azepine-1-carboxylic acid isopropyl ester,
(S) -9-{(3,5-bis-trifluoromethyl-benzyl)-[2- (2-hydroxy-ethyl) -2H-tetrazol-5-yl] -amino} -2,3,6 7,8,9-hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(R) -9-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,6,7,8,9- Hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(S) -9-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,6,7,8,9- Hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid isopropyl ester,
(S) -6-{(3,5-bis-trifluoromethyl-benzyl)-[2- (2-hydroxy-ethyl) -2H-tetrazol-5-yl] -amino} -2,3,6 7,8,9-hexahydro-1H-10-aza-cyclohepta [e] indene-10-carboxylic acid isopropyl ester,
(S) -6-{(3,5-bis-trifluoromethyl-benzyl)-[2- (2-hydroxy-ethyl) -2H-tetrazol-5-yl] -amino} -4-methyl-2, 3,6,7,8,9-hexahydro-1H-10-aza-cyclohepta [e] indene-10-carboxylic acid isopropyl ester,
(S) -9-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,6,7,8,9- Hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid 2-methoxycarbonyl-2-methyl-propyl ester,
(S) -9-[(3,5-Bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,6,7,8,9- Hexahydro-1H-5-aza-cyclohepta [f] indene-5-carboxylic acid 2-carboxy-2-methyl-propyl ester,
(S) -1- {5-[(3,5-bis-trifluoromethyl-benzyl) -2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl- 2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -3-furan-2-ylmethoxy) -propan-2-one,
2- {5-[(3,5-bis-trifluoromethyl-benzyl) -2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2,3 4,5-tetrahydro-benzo [b] azepin-1-yl} -1-phenyl-ethanol,
2- {5-[(3,5-bis-trifluoromethyl-benzyl) -2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2,3 4,5-tetrahydro-benzo [b] azepin-1-yl} -2-phenyl-ethanol,
(S) -4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -benzoic acid methyl ester,
(S) -4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -benzoic acid,
(S) -3- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -benzoic acid methyl ester,
(S) -3- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -benzoic acid,
(S) -4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -benzoic acid,
(4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(3-methyl-isoxazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2,3 , 4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -cyclohexyl) -acetic acid methyl ester,
(4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(3-methyl-isoxazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2,3 , 4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -cyclohexyl) -acetic acid,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-pyridin-4-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [B] Azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-pyridin-4-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [B] Azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine hydrochloride,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-pyridin-3-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [B] Azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopropylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b Azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S) -2- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-ethyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -ethanol,
(S)-(2- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-ethyl-8-trifluoro Methyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -ethyl) -carbamic acid tert-butyl ester,
(S) -4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-ethyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -benzoic acid,
(S) 5- {9-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -1,3,6,7,8, 9-hexahydro-2-oxa-5-aza-cyclohepta [f] inden-5-ylmethyl} -thiophene-2-carboxylic acid,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-(5-pyridin-4-ylmethyl-3,5,6,7,8 , 9-hexahydro-1H-2-oxa-5-aza-cyclohepta [f] inden-9-yl) -amine,
(S)-(4- {9-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -1,3,6,7, 8,9-hexahydro-2-oxa-5-aza-cyclohepta [f] inden-5-ylmethyl} -cyclohexyl) -acetic acid,
(S) -2- {9-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -1,3,6,7,8 , 9-hexahydro-2-oxa-5-aza-cyclohepta [f] inden-5-yl} -ethanol,
(S) -9-[[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl) -amino] -1,3,6 7,8,9-hexahydro-2-oxa-5-aza-cyclohepta [f] indene-5-carboxylic acid tert-butyl ester,
(S)-[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(5-benzyl-3,5,6,7,8,9-hexahydro-1H-2-oxa-5 Aza-cyclohepta [f] inden-9-yl)-(3,5-bis-trifluoromethyl-benzyl) -amine,
(S)-[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-[5- (3,3,3-trifluoro) -Propyl) -3,5,6,7,8,9-hexahydro-1H-2-oxa-5-aza-cyclohepta [f] inden-9-yl] -amine,
(S) -5- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -2,3,4,5,7 , 8,9,10-octahydro-naphtho [2,3-b] azepin-1-yl} -3,3-dimethyl-pentanoic acid,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopentylmethyl-11-methyl-2,3,4,5,7,8,9,10-octahydro-1H-naphtho [ 2,3-b] azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S) -5- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -thiophene-2-carboxylic acid,
(S) -5- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -2-methyl-propionic acid ethyl ester,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(1,7-dimethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepine-5 -Yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-(7-methyl-1-thiazol-2-ylmethyl-8-trifluoromethyl) -2,3,4,5-tetrahydro-1H-benzo [b] azepin-5-yl) -amine,
(S)-(3,5-bis-trifluoromethyl-benzyl)-[7-methyl-1- (1-methyl-1H-imidazol-2-ylmethyl) -8-trifluoromethyl-2,3,4 , 5-tetrahydro-1H-benzo [b] azepin-5-yl]-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-(1-Benzyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepin-5-yl)-(3,5-bis-tri Fluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S) -5- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl},
(S)-(4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoro Methyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -phenyl) -acetic acid,
(S) -4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -butyric acid,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-piperidin-4-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [B] Azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-(4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoro Methyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -piperidin-1-yl) -acetic acid ethyl ester,
(S)-(4- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoro Methyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-ylmethyl} -piperidin-1-yl) -acetic acid,
(S) -3- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl -2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -2-methyl-propionic acid,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-pyrrolidin-2-ylmethyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [B] Azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl) -amine,
(S)-{5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2 , 3,4,5-tetrahydro-benzo [b] azepin-1-yl} -acetic acid,
(S)-[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-[1- (2-benzyloxy-ethyl) -7-methyl-8-trifluoromethyl-2,3 4,5-tetrahydro-1H-benzo [b] azepin-5-yl]-(3,5-bis-trifluoromethyl-benzyl) -amine,
(S) -2- {5-[[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl) -amino] -7-methyl -8-trifluoromethyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -ethanol,
(S) -5-[[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl) -amino] -7-methyl-8- Trifluoromethyl-2,3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid tert-butyl ester,
(S)-[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-(7-methyl-1-thiazol-2-ylmethyl) -8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepin-5-yl) -amine,
(S)-(2- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoro Methyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -ethoxy) -acetic acid,
(S) -Acetic acid 2- {5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoro Methyl-2,3,4,5-tetrahydro-benzo [b] azepin-1-yl} -ethyl ester,
(S)-(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl)-[7-methyl-1- (2H-tetrazol-5-ylmethyl) -8 -Trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepin-5-yl] -amine,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid 2-amino-ethyl ester,
(S) -5-[(3,5-bis-trifluoromethyl-benzyl)-(2-methyl-2H-tetrazol-5-yl) -amino] -7-methyl-8-trifluoromethyl-2, 3,4,5-tetrahydro-benzo [b] azepine-1-carboxylic acid 2-carboxy-2-methyl-propyl ester,
(S)-[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopropylmethyl-7-methyl-8) -Trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepin-5-yl) -amine,
(S)-[2- (2-Amino-ethyl) -2H-tetrazol-5-yl]-(3,5-bis-trifluoromethyl-benzyl)-(1-cyclopropylmethyl-7-methyl-8) -Trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo [b] azepin-5-yl) -amine hydrochloride
Or a pharmacologically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof selected from the group consisting of
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58270804P | 2004-06-24 | 2004-06-24 | |
US60/582,708 | 2004-06-24 | ||
US62724104P | 2004-11-12 | 2004-11-12 | |
US60/627,241 | 2004-11-12 | ||
US66486205P | 2005-03-24 | 2005-03-24 | |
US60/664,862 | 2005-03-24 | ||
PCT/US2005/022389 WO2006002342A1 (en) | 2004-06-24 | 2005-06-23 | Compounds and methods for treating dyslipidemia |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008504277A JP2008504277A (en) | 2008-02-14 |
JP2008504277A5 true JP2008504277A5 (en) | 2008-08-07 |
JP4836945B2 JP4836945B2 (en) | 2011-12-14 |
Family
ID=35056992
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007518182A Pending JP2008504266A (en) | 2004-06-24 | 2005-06-22 | Compounds and methods for treating dyslipidemia |
JP2007518296A Expired - Fee Related JP4836945B2 (en) | 2004-06-24 | 2005-06-23 | Compounds and methods for treating dyslipidemia |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007518182A Pending JP2008504266A (en) | 2004-06-24 | 2005-06-22 | Compounds and methods for treating dyslipidemia |
Country Status (27)
Country | Link |
---|---|
US (3) | US20080269284A1 (en) |
EP (3) | EP1761521A1 (en) |
JP (2) | JP2008504266A (en) |
KR (1) | KR20070041452A (en) |
CN (1) | CN1972932B (en) |
AT (1) | ATE528304T1 (en) |
AU (2) | AU2005267436A1 (en) |
BR (2) | BRPI0512523A (en) |
CA (2) | CA2570688A1 (en) |
CR (1) | CR8831A (en) |
CY (1) | CY1112124T1 (en) |
DK (1) | DK1761522T3 (en) |
EA (2) | EA200700119A1 (en) |
EC (2) | ECSP067095A (en) |
ES (1) | ES2372291T3 (en) |
HK (1) | HK1104528A1 (en) |
HR (1) | HRP20110761T1 (en) |
IL (2) | IL180277A (en) |
MA (2) | MA28729B1 (en) |
MX (2) | MXPA06014716A (en) |
NO (2) | NO20070470L (en) |
NZ (1) | NZ550978A (en) |
PL (1) | PL1761522T3 (en) |
PT (1) | PT1761522E (en) |
RS (1) | RS52064B (en) |
SI (1) | SI1761522T1 (en) |
WO (2) | WO2006012093A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1863778A (en) * | 2003-10-08 | 2006-11-15 | 伊莱利利公司 | Compounds and methods for treating dyslipidemia |
DE602005014955D1 (en) | 2004-03-26 | 2009-07-30 | Lilly Co Eli | COMPOUNDS AND METHOD FOR THE TREATMENT OF DYSLIPIDEMIA |
UA90269C2 (en) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Tetrahydroquinoline derivatives and a process for preparing the same |
JP2008504266A (en) | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | Compounds and methods for treating dyslipidemia |
WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
WO2008017381A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
DE102007005045B4 (en) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazine derivatives, process for their preparation and their use as medicines |
WO2008143127A1 (en) * | 2007-05-17 | 2008-11-27 | Ajinomoto Co., Inc. | Method of measuring the activity of lipid-modified enzyme |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
DE102007063671A1 (en) | 2007-11-13 | 2009-06-25 | Sanofi-Aventis Deutschland Gmbh | New crystalline diphenylazetidinone hydrates, medicaments containing these compounds and their use |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
AR077208A1 (en) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | ACID DERIVATIVES TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFLUOROMETIL) PHENYLE] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO) -2,3, 4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL) METHYL) -CYCLHEXANCARBOXYL AND ITS CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT, ITS USE TO PREPARE A MEDICAM |
SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683702B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120056A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120052A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
ES2683350T3 (en) * | 2011-07-08 | 2018-09-26 | Novartis Ag | Method to treat atherosclerosis in subjects with high triglycerides |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
NO2860175T3 (en) * | 2012-06-11 | 2018-04-28 | ||
CN103958501B (en) * | 2012-07-16 | 2016-08-17 | 上海恒瑞医药有限公司 | Benzo seven membered heterocyclic analog derivative, its preparation method and in application pharmaceutically |
RS58329B1 (en) * | 2014-02-05 | 2019-03-29 | Dezima Pharma B V | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
CN103833637B (en) * | 2014-03-31 | 2016-01-06 | 武汉武药制药有限公司 | One prepares the method according to bent (Evacetrapib) intermediate of plug |
JP6549735B2 (en) | 2015-06-09 | 2019-07-24 | アッヴィ・インコーポレイテッド | Nuclear receptor modulator |
WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2402506A1 (en) * | 1977-09-09 | 1979-04-06 | Guelennec Emile Le | SHEAR FOR CUTTING LARGE SCRAP |
GT199900147A (en) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
HN2000000203A (en) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | PROCEDURE FOR OBTAINING 1,2,3,4-TETRAHYDROQUINOLINS 4-CARBOXYAMIN-2-SUBSTITUTED. |
CO5271716A1 (en) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED |
DK1383734T3 (en) * | 2001-04-30 | 2006-05-15 | Pfizer Prod Inc | Compounds useful as intermediates for 4-aminoquinoline derivatives |
PT1533292E (en) | 2002-08-30 | 2007-05-31 | Japan Tobacco Inc | Dibenzylamine compound and medicinal use thereof |
JP2006508077A (en) | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | PGD2 receptor antagonist for the treatment of inflammatory diseases |
WO2004078730A2 (en) | 2003-03-04 | 2004-09-16 | Takasago International Corporation | Method for producing optically active amines |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
CN1863778A (en) | 2003-10-08 | 2006-11-15 | 伊莱利利公司 | Compounds and methods for treating dyslipidemia |
DE602005014955D1 (en) | 2004-03-26 | 2009-07-30 | Lilly Co Eli | COMPOUNDS AND METHOD FOR THE TREATMENT OF DYSLIPIDEMIA |
UA90269C2 (en) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Tetrahydroquinoline derivatives and a process for preparing the same |
JP2008504266A (en) | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | Compounds and methods for treating dyslipidemia |
WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
AR077208A1 (en) * | 2009-06-30 | 2011-08-10 | Lilly Co Eli | ACID DERIVATIVES TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFLUOROMETIL) PHENYLE] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO) -2,3, 4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL) METHYL) -CYCLHEXANCARBOXYL AND ITS CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT, ITS USE TO PREPARE A MEDICAM |
-
2005
- 2005-06-22 JP JP2007518182A patent/JP2008504266A/en active Pending
- 2005-06-22 US US11/570,540 patent/US20080269284A1/en not_active Abandoned
- 2005-06-22 AU AU2005267436A patent/AU2005267436A1/en not_active Abandoned
- 2005-06-22 WO PCT/US2005/021789 patent/WO2006012093A1/en active Application Filing
- 2005-06-22 BR BRPI0512523-5A patent/BRPI0512523A/en not_active Application Discontinuation
- 2005-06-22 KR KR1020067027038A patent/KR20070041452A/en not_active Application Discontinuation
- 2005-06-22 CA CA002570688A patent/CA2570688A1/en not_active Abandoned
- 2005-06-22 EP EP05768995A patent/EP1761521A1/en not_active Withdrawn
- 2005-06-22 EA EA200700119A patent/EA200700119A1/en unknown
- 2005-06-22 MX MXPA06014716A patent/MXPA06014716A/en not_active Application Discontinuation
- 2005-06-23 NZ NZ550978A patent/NZ550978A/en not_active IP Right Cessation
- 2005-06-23 RS RS20110559A patent/RS52064B/en unknown
- 2005-06-23 CN CN2005800206855A patent/CN1972932B/en not_active Expired - Fee Related
- 2005-06-23 AT AT05763328T patent/ATE528304T1/en active
- 2005-06-23 EA EA200700120A patent/EA012585B1/en not_active IP Right Cessation
- 2005-06-23 PL PL05763328T patent/PL1761522T3/en unknown
- 2005-06-23 US US11/570,542 patent/US7786108B2/en not_active Expired - Fee Related
- 2005-06-23 PT PT05763328T patent/PT1761522E/en unknown
- 2005-06-23 SI SI200531438T patent/SI1761522T1/en unknown
- 2005-06-23 EP EP05763328A patent/EP1761522B1/en active Active
- 2005-06-23 MX MXPA06014706A patent/MXPA06014706A/en active IP Right Grant
- 2005-06-23 DK DK05763328.1T patent/DK1761522T3/en active
- 2005-06-23 WO PCT/US2005/022389 patent/WO2006002342A1/en active Application Filing
- 2005-06-23 BR BRPI0512516-2A patent/BRPI0512516A/en active Search and Examination
- 2005-06-23 EP EP11184746A patent/EP2479175A1/en not_active Withdrawn
- 2005-06-23 JP JP2007518296A patent/JP4836945B2/en not_active Expired - Fee Related
- 2005-06-23 ES ES05763328T patent/ES2372291T3/en active Active
- 2005-06-23 CA CA2570673A patent/CA2570673C/en not_active Expired - Fee Related
- 2005-06-23 AU AU2005258241A patent/AU2005258241B2/en not_active Ceased
-
2006
- 2006-12-19 EC EC2006007095A patent/ECSP067095A/en unknown
- 2006-12-19 EC EC2006007098A patent/ECSP067098A/en unknown
- 2006-12-22 CR CR8831A patent/CR8831A/en unknown
- 2006-12-24 IL IL180277A patent/IL180277A/en not_active IP Right Cessation
- 2006-12-24 IL IL180276A patent/IL180276A0/en unknown
- 2006-12-29 MA MA29595A patent/MA28729B1/en unknown
- 2006-12-29 MA MA29596A patent/MA28730B1/en unknown
-
2007
- 2007-01-24 NO NO20070470A patent/NO20070470L/en not_active Application Discontinuation
- 2007-01-24 NO NO20070468A patent/NO20070468L/en not_active Application Discontinuation
- 2007-08-17 HK HK07109002.0A patent/HK1104528A1/en not_active IP Right Cessation
-
2010
- 2010-04-20 US US12/763,344 patent/US20100204207A1/en not_active Abandoned
-
2011
- 2011-10-19 HR HR20110761T patent/HRP20110761T1/en unknown
- 2011-11-25 CY CY20111101160T patent/CY1112124T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008504277A5 (en) | ||
HRP20110761T1 (en) | Compounds and methods for treating dyslipidemia | |
RU2630677C2 (en) | Compounds | |
US20040171606A1 (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | |
RU2008136187A (en) | NEW CUMARIN DERIVATIVE WITH ANTITUMOR ACTIVITY | |
JP2018528192A (en) | Composition comprising PI3K inhibitor and HDAC inhibitor | |
JP2008504266A5 (en) | ||
WO2014014874A1 (en) | Pyrazole derivatives which inhibit leukotriene production | |
KR20150064753A (en) | Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives | |
JP2006514989A5 (en) | ||
RU2008141761A (en) | C-MET PROTEINKINASE INHIBITORS | |
NZ588266A (en) | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | |
JP2008525417A5 (en) | ||
RU2017118165A (en) | Homolog Enhancer 2 Zestes Inhibitors | |
AU2007224660A1 (en) | Thiazoles as NF-KB inhibitors (proteasome inhibitors) | |
JPWO2002072145A1 (en) | A therapeutic agent for depression containing an EP1 antagonist as an active ingredient | |
TW200932221A (en) | Imidazole carbonyl compounds | |
RU2008141511A (en) | CONDENSED HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS MGLUR5 MODULATORS | |
US11191747B2 (en) | Pyrrole compounds | |
WO2020161257A1 (en) | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors | |
JP2019529445A5 (en) | ||
US20220119395A1 (en) | Bicyclic compounds | |
US8846660B2 (en) | Seven-membered ring compound and pharmaceutical use therefor | |
CA2506716A1 (en) | Carboxamides | |
JP2003516994A5 (en) |